Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 14.14 M
The data is delayed by 15 minutes.
ACST is in the long-term down -98% below S&P in 11 years.
Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
|Shares Outstanding||10.71 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||ROE||ROI|
|Current Ratio||Quick Ratio||Long Term Debt/Equity||Debt Ratio|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||Cash From Operating Activities||Gross Profit|
|Net Profit||Operating Profit||Total Assets||Total Current Assets|
|Total Current Liabilities||Total Debt||Total Liabilities||Total Revenue|
|High 52 week||3.1||Low 52 week||0.63||Last close||0.71||Last change||1.59%|
|RSI||36.35||Average true range||0.04||Beta||0.3||Volume||4.94 M|
|Simple moving average 20 days||-2.49%||Simple moving average 50 days||-23.16%||Simple moving average 200 days||-39.8%|
|Performance Week||7.92%||Performance Month||-34.26%||Performance Quart||-31.73%||Performance Half||-44.96%|
|Performance Year||-43.2%||Performance Year-to-date||-24.69%||Volatility daily||6.55%||Volatility weekly||14.65%|
|Volatility monthly||30.03%||Volatility yearly||104.04%||Relative Volume||5202.7%||Average Volume||196.58 K|
|New High||New Low|
2020-05-06 06:25:05 | Does The Acasti Pharma Inc. CVE:ACST Share Price Fall With The Market?
2020-04-30 08:30:10 | Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA
2020-03-06 06:50:52 | Amarin Stock Looks Like a Heart-Healthy Buy on the Dip
2020-02-28 17:00:10 | Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
2020-02-28 14:48:40 | Look Anywhere but Acasti Pharma Stock for Opportunity
2020-02-28 10:07:03 | Confounding Decline Creates an Opportunity in Amarin Stock
2020-02-14 11:41:45 | Risks Remain, but Amarin Stock Is a Buy at Today’s Prices
2020-02-14 08:00:10 | Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020
2020-02-13 09:00:10 | Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call
2020-02-11 11:27:42 | 3 Beaten-Down Biotech Stocks With +50% Upside Potential
2020-02-10 07:00:10 | Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre
2020-01-17 11:07:12 | Does Acasti Stock Have a Future?
2020-01-17 06:30:07 | Why Amarin Stock Is Poised for a Healthy 2020
2020-01-14 09:46:02 | AstraZeneca to End Phase III Study on Fish Oil Heart Drug
2020-01-13 16:22:46 | This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled
2020-01-13 14:31:00 | Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint
2020-01-13 13:38:00 | Neptune Provides Updates on Non-Core Investments
2020-01-13 11:07:00 | Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall Short
2020-01-13 09:40:46 | This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled
2020-01-13 06:00:10 | Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
2020-01-10 10:59:53 | All Bets Are Off for Amarin Stock
2020-01-09 08:56:44 | 3 Healthcare Stocks With Big Catalysts in January
2019-12-24 09:51:09 | Acasti Delays Data Readout For Drug To Treat Elevated Triglycerides
2019-12-22 16:43:00 | Hedge Funds Have Never Been This Bullish On Acasti Pharma Inc. ACST
2019-12-20 04:41:30 | Amarin Stock is at Sky-High Levels Already Assumes All the Good News
2019-11-25 08:30:00 | Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.
2019-11-21 08:23:01 | Amarin's Shares Down on Underperform Rating by Oppenheimer
2019-11-13 07:55:00 | Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020
2019-11-06 09:00:00 | Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call
2019-11-04 09:04:06 | Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®
2019-10-01 09:00:00 | Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
2019-09-27 06:05:30 | Do Insiders Own Lots Of Shares In Acasti Pharma Inc. CVE:ACST?
2019-08-14 08:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020
2019-08-07 08:00:00 | Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call